Pharma sector outlook: ICRA pegs 7-9% revenue growth for FY26, US headwinds cloud prospects
India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products.🕒 1 min read
India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products.
Continue Reading
- Hormuz chaos nears month 3: Oil prices climb as tightened supplies squeeze fuel reserves
- ED attaches Rs 582 crore land assets linked to Anil Ambani, companies
- Pak Teen Gets 100-Year Jail Term For Killing 4 Family Members Over PUBG Game
- ‘Good stocks in hand’: India well placed on crude, fuel despite Middle East war, says Goyal
-
4, Including A Newborn, Killed As Car Falls In Canal In Uttarakhand’s Haldwani
- স্লটের বোনাস ফিচার তুলনা করার সঠিক পদ্ধতি Jita Bet এ
-
“Nothing Like Home”: Indians Return From Middle East, Recount Mid-Air Scares
- Menstrual Hygiene Day 2025 — 9 Surprising Facts About Menstrual Health
- IndiGo says pilot strength adequate as DGCA’s temporary duty norm relaxations end
- Stock market holiday: Will NSE, BSE remain closed on October 2? Check full list of October holidays
